Title of cohort

    The Health Survey in Nord-Trøndelag

    Acronym for cohort

    HUNT

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Steinar

    Name of Principal Investigator - Last name

    Krokstad

    Address of institution -Institution

    HUNT Research Center NTNU (Norwegian University of Science and Technology)

    Address of institution - Street address

    Forskningsvegen 2

    Address of institution - City

    Levanger

    Address of institution - Postcode

    7600

    Country

    Norway

    Website
    Contact email
    Funding source

    Public funding source for NTNU, but also for the wider research community nationally and internationally.

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Parkinson's disease and PD-related disorders|Alzheimer's disease and other dementias|Neurodegenerative disease in general

    Q1b. When are studies on the above condition(s) expected to become possible?

    Already possible

    Q2a. In a single sentence what is the stated aim of the cohort?

    To study health and diseases in the general population and the effects of environmental and genetic interactions to identify potential causes of diseases as well as preventive strategies

    Q2b. What distinguishes this cohort from other population cohorts?

    It is longitudinal and prospective with repeated measures and covers the entire population above the age of 13 within one county of Norway. It has been conducted since 1984 and a wide variaty of disease outcomes have been identified based on linkage to registry data.

    Q3a. i) Number of publications that involve use of your cohort to date

    Approx 1600

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Kristian Hveem, NTNU, Studying genes affecting cardiovsacular traits|Kristian Hveem, NTNU, Studying genes affecting cardiovsacular traits|Geir Selbæk, University of Oslo, Cognitive impairment and the risk of Alzheimers disease (HUNT4)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    1) Holmen OL et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat genet, 2014, April, 46(4) 3) Bergh S et al, Cohort profile: the Health and Memory Study (HMS): a dementia cohort linked to the HUNT study in Norway, Int J of Epidem, 2014 Dec 43(6)

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    13

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    Resident in the county

    Q4c. Study criteria: what are the exclusion criteria?

    Not a resident in the county

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    More than 15,000 participants

    Q6a. Please describe what measures are used to characterise participants

    Questionairre data, clinical measurements, biological samples, linkage to local, regional and national health registries

    Q6b. Are there additional measures for participants with a clinical disorder?

    Yes, for several

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    Yes

    If yes please specify

    Type 2 Diabetes, Myocardial Infarction, Dementia and several others

    Q7. What is the study design (select all that apply)?

    Prospective cohort|Longitudinal|Cross sectional survey

    Q8. Are your cases matched by

    Age

    Q9a. Does your study include a specialised subset of control participants?

    No

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. i) Please enter the data collection start date

    01/08/1984

    Q10a. ii) Please enter the data collection end date

    01/02/2019

    Q10a. iii) Is data collection for this study

    At the planning stage|Data analysis ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - funding applied for/funding awarded

    Q11. Is data collected

    Through links to medical records

    Other please specify here

    Also to other registries, such a prescription, familiy, birth, CVD, cause of death, fractures, income, disabilty pensions and many orthers

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    Yes (participants given permission to be re-contacted via PIs)

    Q13a. Please give information on the format and availability of data stored in a database (1)

    Data summarised in database

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (2)

    Database is web-based

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (3)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (2)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (4)

    % available

    Please specify language used

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource|Access independent of collaboration with PI|Access committee mechanism|Local/ regional access|National access|International access|Access to industry|Access for pilot studies permitted|Access restricted to peer-reviewed work|Applicant needs to provide separate external ethics approval

    Q15. What data sharing policy is specified as a condition of use?

    Data made publicly available after a specified time point

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below:

    Living donors: blood|Living donors: blood derivatives|Living donors: DNA| Living donors: other, please specify below|Post-mortem donors: other - FFPE-samples may be retrieved and accessed through the Dept of Pathology, St Olav's Hospital, Trondheim

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Primary samples: Supplied fresh| Primary Samples: Stabilised samples (frozen or fixed)|Secondary samples: plasma|Secondary samples: DNA|Secondary samples: RNA|Immortalized cells

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: Norway
Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF